Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

News Conference News ESC 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

September 02, 2024

Stuart J. Connolly, Clinical Trialist and Arrhythmia Medicine Pioneer, Dies at 75

News Daily News

Stuart J. Connolly, Clinical Trialist and Arrhythmia Medicine Pioneer, Dies at 75

June 04, 2024

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

Wearables Under the Microscope: How New Tech Will Disrupt Patient-Physician Dynamics

News Features

Wearables Under the Microscope: How New Tech Will Disrupt Patient-Physician Dynamics

Marcus A. Banks

August 15, 2019

2018 North American Consensus Statement for Atrial Fibrilation Patients Undergoing PCI

Podcast TCTMD Talking Points

Atrial Fibrillation and PCI

January 02, 2019

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

CABANA Misses Primary Endpoint, but Electrophysiologists See Support for Ablation

News Conference News HRS 2018

CABANA Misses Primary Endpoint, but Electrophysiologists See Support for Ablation

May 10, 2018

Live From Denver: TCT 2017, Day Four

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Four

November 02, 2017

Episode 28: The AMULET Observational Study

Podcast TCTMD Talking Points

Episode 28: The AMULET Observational Study

August 23, 2017

Episode 27: The WATCHMAN US Postapproval Study

Podcast TCTMD Talking Points

Episode 27: The WATCHMAN US Postapproval Study

August 16, 2017

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.